danoff, I think LDX's share price may have been impacted by the...

danoff, I think LDX's share price may have been impacted by the release of some shares from escrow, whereas,
AT1 decline may have more to do with a lack of guidance. Whilst it was noted that Covid sales for the
current FY 22 have already surpassed FY21, we have little to no guidance on expected Revenue for 21/22.
Just more of the same from the company, in discussions with potential partners, bah, bah, bah.

In saying the above, after reading the announcement from LDX, it was positive to see their
optimism around the potential of FebriDx, especially post FDA approval ( fingers crossed).
AT1 will inadvertently benefit from any success of FebriDx.